Hereditary angioedema

• Skin - the most common sites are the face (such as the lips and eyes), hands, arms, legs, genitals, and buttocks. Skin swelling can cause pain, dysfunction, and disfigurement, although it is generally not dangerous and is temporary.
• Gastrointestinal tract - the stomach, intestines, bladder, and/or urethra may be involved. This may cause symptoms such as nausea, vomiting, diarrhea, and abdominal pain.
• Upper airway (such as the larynx and tongue) - this can cause upper airway obstruction and may be life-threatening. The majority of attacks affecting the airway resolve before complete airway obstruction.

Attacks may involve one area of the body at a time, or they may involve a combination of areas. They always go away on their own but last from 2 to 4 days. While people with HAE have reported various triggers of attacks, emotional stress, physical stress, and dental procedures are the most commonly reported triggers.^[2]

There are several types of HAE.^[1] Types I and II are caused by mutations in the C1NH gene (also called the SERPING1 gene), which provides instructions for making the C1 inhibitor protein.^[1][3] Type I is due to deficiency of C1 inhibitor, and type II is due to dysfunction of C1 inhibitor.^[1] These types are also characterized by abnormal complement protein levels. Inheritance of types I and II is autosomal dominant, but not all people with a SERPING1 gene mutation will develop symptoms of HAE. A third type is called HAE with normal C1 inhibitor. This type is characterized by normal C1 inhibitor and normal complement protein levels, and usually begins in adulthood.^[4] While some cases of type III are due to mutations in the F12 gene, in other cases the cause is not yet known.^[1][5] The inheritance of this form is also thought to be autosomal dominant.^[4]

Management of HAE involves treatment of sudden (acute) attacks and preventing attacks (prophylaxis).^[3] Treatment for acute attacks in types I and II includes replacement with C1 inhibitor concentrates, a kallikrein inhibitor, or fresh-frozen plasma (by infusion).^[3] Sudden attacks involving the upper airway may involve intubation if stridor or signs of respiratory distress are present.^[4] HAE with normal C1 inhibitor levels is treated similarly, however C1 inhibitor infusion is not effective. Prophylaxis may involve regular injections of C1 inhibitor concentrates, long-term androgen (male hormone) therapy, or antifibrinolytics.^[3][6]

The long-term outlook varies depending on the frequency and location of attacks, and the severity of attacks in each person. Attacks generally continue throughout life, but the frequency of attacks can be significantly reduced with therapy.^[2]

Related diseases are conditions that have similar signs and symptoms. A health care provider may consider these conditions in the table below when making a diagnosis. Please note that the table may not include all the possible conditions related to this disease.

NCATS Co-Sponsored Conferences

• Hereditary Angioedema (HAE) Conference Friday, September 19, 2014 - Saturday, September 20, 2014
  Location: San Diego, CA

  Description: Anticipated goals and use of results: 1) Organize and conduct a conference that is thematically focused on growing and extending knowledge in HAE; and which become progressively more ambitious over time, reflecting the anticipated advances in research. 2) Identify topics and speakers that will clarify the most promising avenues of investigation, organize the conference in a manner that will optimally support communication between all participants, communicate the resulting discussions to the broader scientific, patient, and pharmaceutical communities. 3) Provide a supportive and constructive forum for young investigators, including female and minority scientists, to present their work and interact with more senior investigators. 4) Increase interest and awareness of HAE research among the wider research community particularly among young investigators in order to recruit new investigators into the field. 5) Ensure equal representation and access of women and underrepresented minority participants.

  Contact: Nancy Coulter,(301) 496-1886, ncoulter@niaid.nih.gov

  Co-funding Institute(s): National Institute of Allergy and Infectious Diseases, Office of Rare Diseases Research

Questions sent to GARD may be posted here if the information could be helpful to others. We remove all identifying information when posting a question to protect your privacy. If you do not want your question posted, please let us know.